Baxter International Inc. (BAX): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Baxter International ( BAX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.9%. By the end of trading, Baxter International rose $0.72 (1.0%) to $69.85 on average volume. Throughout the day, 4,331,358 shares of Baxter International exchanged hands as compared to its average daily volume of 2,901,100 shares. The stock ranged in a price between $69.25-$70.17 after having opened the day at $69.45 as compared to the previous trading day's close of $69.13. Other companies within the Health Care sector that increased today were: Sucampo Pharmaceuticals Inc. A ( SCMP), up 24.1%, Celsion Corporation ( CLSN), up 15.0%, Oramed Pharmaceuticals ( ORMP), up 13.6% and Illumina ( ILMN), up 13.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.5 billion and is part of the health services industry. The company has a P/E ratio of 16.4, below the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year to date as of the close of trading on Monday.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Biota Pharmaceuticals ( BOTA), down 61.1%, iBio ( IBIO), down 13.5%, Catalyst Pharmaceutical Partners ( CPRX), down 13.2% and ARCA biopharma ( ABIO), down 11.0% , were all laggards within the health care sector with Idexx Laboratories ( IDXX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Gold Is Great Again Thanks to North Korea's Kim Jong-Un

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

These Stocks Are Ready to Reverse Course